tiprankstipranks
Adagene (ADAG)
NASDAQ:ADAG
US Market
ADAG
Adagene
RESEARCH TOOLSreports
Want to see ADAG full AI Analyst Report?

Adagene (ADAG) Stock News & Sentiment

113 Followers
Analyst Initiates Buy on Muza Developer, Citing Promising MSS CRC Data, Clear Registrational Path, and Broader Expansion Upside Despite Cash Constraints
Premium
Ratings
Analyst Initiates Buy on Muza Developer, Citing Promising MSS CRC Data, Clear Registrational Path, and Broader Expansion Upside Despite Cash Constraints
12d ago
ADAG
Adagene Showcases Promising Muzastotug Triplet Data at AACR 2026 for Liver and Colorectal Cancers
Premium
Company Announcements
Adagene Showcases Promising Muzastotug Triplet Data at AACR 2026 for Liver and Colorectal Cancers
21d ago
6K
ADAG
Adagene: Deepening Dose‑Response Evidence and Strategic Partnership Support Buy Rating on Lead CTLA‑4 Program
Premium
Ratings
Adagene: Deepening Dose‑Response Evidence and Strategic Partnership Support Buy Rating on Lead CTLA‑4 Program
1M ago
ADAG
Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer
Premium
Company Announcements
Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer
1M ago
6K
ADAG
Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline
Premium
Company Announcements
Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline
1M ago
6K
ADAG
Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028
Premium
Company Announcements
Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028
1M ago
6K
ADAG
Adagene (ADAG): De-Risked CTLA-4 Asset, Emerging Regulatory Clarity, and Strategic Partnerships Underpin Buy Rating
Premium
Ratings
Adagene (ADAG): De-Risked CTLA-4 Asset, Emerging Regulatory Clarity, and Strategic Partnerships Underpin Buy Rating
3M ago
ADAG
More ADAG News >

ADAG News on the Web

Adagene Showcases Promising Muzastotug Triplet Data at AACR 2026 for Liver and Colorectal Cancers
TipRanks News
Bullish
Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG), Caribou Biosciences (CRBU) and Praxis Precision Medicines (PRAX)
TipRanks News
Bullish
Guggenheim Keeps Their Buy Rating on Adagene (ADAG)
TipRanks News
Neutral
Adagene: Deepening Dose‑Response Evidence and Strategic Partnership Support Buy Rating on Lead CTLA‑4 Program
TipRanks News
Bullish
Adagene price target raised to $10 from $9 at Guggenheim
TipRanks News
Bullish
Adagene 18.666M share Spot Secondary priced at $3.75
TipRanks News
Neutral
Adagene enters pact with Incyte for combination of muzastotug, INCA33890
TipRanks News
Neutral

News Score - Last 7 Days

Positive
ADAG
Sector Average
Media Buzz
This Week2 articles
Weekly Average2.75 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ADAG’s Media Buzz Sentiment?
2 articles about ADAG were published this week. In an average week, 2.75 articles are published.
    What is ADAG’s weekly average amount of articles?
    In an average week, 2.75 articles about ADAG are published.
      What is ADAG’s News Sentiment?
      100% of articles about ADAG were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week